MA71448A - Régimes posologiques pour le traitement d'une neuropathie motrice multifocale (nmm) - Google Patents

Régimes posologiques pour le traitement d'une neuropathie motrice multifocale (nmm)

Info

Publication number
MA71448A
MA71448A MA71448A MA71448A MA71448A MA 71448 A MA71448 A MA 71448A MA 71448 A MA71448 A MA 71448A MA 71448 A MA71448 A MA 71448A MA 71448 A MA71448 A MA 71448A
Authority
MA
Morocco
Prior art keywords
mmn
treatment
dosage regimen
motor neuropathy
multifocal motor
Prior art date
Application number
MA71448A
Other languages
English (en)
Inventor
Inge VAN DE WALLE
Stefaan ROSSENU
Original Assignee
argenx BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by argenx BV filed Critical argenx BV
Publication of MA71448A publication Critical patent/MA71448A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA71448A 2022-07-14 2023-07-13 Régimes posologiques pour le traitement d'une neuropathie motrice multifocale (nmm) MA71448A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263368428P 2022-07-14 2022-07-14
PCT/EP2023/069483 WO2024013300A1 (fr) 2022-07-14 2023-07-13 Régimes posologiques pour le traitement d'une neuropathie motrice multifocale (nmm)
EP23744707.3A EP4554974A1 (fr) 2022-07-14 2023-07-13 Régimes posologiques pour le traitement d'une neuropathie motrice multifocale (nmm)

Publications (1)

Publication Number Publication Date
MA71448A true MA71448A (fr) 2025-04-30

Family

ID=87429584

Family Applications (1)

Application Number Title Priority Date Filing Date
MA71448A MA71448A (fr) 2022-07-14 2023-07-13 Régimes posologiques pour le traitement d'une neuropathie motrice multifocale (nmm)

Country Status (12)

Country Link
US (1) US20250263476A1 (fr)
EP (1) EP4554974A1 (fr)
JP (1) JP2025522989A (fr)
KR (1) KR20250039391A (fr)
CN (1) CN119585305A (fr)
AU (1) AU2023305091A1 (fr)
CA (1) CA3259060A1 (fr)
IL (1) IL318325A (fr)
MA (1) MA71448A (fr)
MX (1) MX2024015984A (fr)
TW (1) TWI846542B (fr)
WO (1) WO2024013300A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025146509A1 (fr) * 2024-01-05 2025-07-10 argenx BV Méthodes de traitement d'une neuropathie motrice multifocale (nmm)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy

Also Published As

Publication number Publication date
KR20250039391A (ko) 2025-03-20
TWI846542B (zh) 2024-06-21
MX2024015984A (es) 2025-02-10
TW202408574A (zh) 2024-03-01
CN119585305A (zh) 2025-03-07
IL318325A (en) 2025-03-01
WO2024013300A1 (fr) 2024-01-18
EP4554974A1 (fr) 2025-05-21
CA3259060A1 (fr) 2024-01-18
JP2025522989A (ja) 2025-07-17
US20250263476A1 (en) 2025-08-21
AU2023305091A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
EP4021500A4 (fr) Procédés pour le traitement d'une maladie oculaire thyroïdienne
Haringman et al. A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis
MA47313A (fr) Formulations sous-cutanées d'anticorps her2
MA55214A (fr) Composés, compositions et procédés pour le traitement d'une maladie
EP3877418A4 (fr) Schéma posologique d'anticorps anti-tigit pour le traitement du cancer
EP3911329A4 (fr) Composition pour la prévention ou le traitement d'une maladie du foie métabolique
EP3986863A4 (fr) Inhibiteurs de glycolate oxydase pour le traitement d'une maladie
BR112021016398A2 (pt) Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
EP3953356C0 (fr) Composés hexahydro-1h-pyrazino[1,2-a]pyrazine pour le traitement d'une maladie auto-immune
EA202193189A1 (ru) Антагонисты системы комплемента для применения в способах лечения парапротеинемических нейропатий
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
EP4054606A4 (fr) Utilisation des vésicules liées à la matrice pour le traitement d'une maladie auto-immune
EP3947390A4 (fr) Compositions et leurs méthode d'utilisation pour le traitement d'une maladie neurodegenerative et mitochondriale
EP4017486A4 (fr) Compositions pour le traitement d'un état caractérisé par une déficience en anandamide et leurs utilisations
EP4129298A4 (fr) Composition pharmaceutique composite pour le traitement d'une maladie de type fibrose
MA47888B1 (fr) Régime de dosage pour agents anti-bcma
Tedeschi et al. First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies
EP4340881A4 (fr) Anticorps pour le traitement d'alpha-synucléinopathies
EP4130025A4 (fr) Composition comprenant un peptide vgll1 pour le traitement du cancer
EP3820477A4 (fr) Composés, compositions et procédés pour le traitement d'une maladie
MX2024015984A (es) Regimenes de dosificacion para el tratamiento de la neuropatia motora multifocal (mmn)
MA52811A (fr) Procédés d'utilisation de cd24 pour la prévention et le traitement d'une rechute de la leucémie
Takehara et al. Post-infectious proliferative glomerulonephritis with monoclonal immunoglobulin G deposits associated with complement factor H mutation
Otoupalova et al. Recurrent chylothorax: a clinical mystery
EP4106874A4 (fr) Compositions et leurs méthodes d'utilisation pour le traitement d'une maladie neurodégénérative et mitochondriale